Onset of dementia is associated with age at menopause in women with Down's syndrome

Annals of Neurology

Volumn 54, Issue 4, 2003, Pages 433-438

  Schupf, Nicole ^a,b,c,g   Pang, Deborah ^b   Patel, Bindu N ^b   Silverman, Wayne ^b   Schubert, Romaine ^b   Lai, Florence ^d   Kline, Jennie K ^c,e,f   Stern, Yaakov ^a,c   Ferin, Michel ^a   Tycko, Benjamin ^a   Mayeux, Richard ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e College of Physicians and Surgeons ^*  (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ESTRADIOL; ESTROGEN; SEX HORMONE BINDING GLOBULIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BODY MASS; DEMENTIA; DEPRESSION; DOWN SYNDROME; ESTROGEN DEFICIENCY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MENOPAUSE; MENTAL DEFICIENCY; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGE OF ONSET; AGING; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BODY MASS INDEX; CASE-CONTROL STUDIES; DEMENTIA; DEPRESSION; DOWN SYNDROME; FEMALE; HORMONES; HUMANS; HYPOTHYROIDISM; INTELLIGENCE; MENOPAUSE; MENTAL STATUS SCHEDULE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 0141646636     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10677     Document Type: Article

References (55)

1. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992;89:4668-4672.
2. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836-1844.
3. Luine VN. Estradiol increases choline acetyltransferase activity in specific basic forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89:484-490.
4. Behl C, Widmann M, Trapp T, Holsboer F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995;216:473-482.
5. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994;269:13065-13068.
6. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998;4:447-451.
7. Greenfield JP, Leung LW, Cai D, et al. Estrogen lowers Alzheimer β-amyloid generation by stimulating trans-golgi network vesicle biogenesis. J Biol Chem 2002;277:12128-12136.
8. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17 beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Neurology 2000;54:2212-2217.
9. Zheng H, Xu K, Uljon SN, et al. Modulation of Aβ peptides by estrogen in mouse models. Neurochemistry 2002;80:191-196.
10. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83: 979-983.
11. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
12. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
13. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
14. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368-373.
15. Yaffe K, Haan M, Byers A, et al. Estrogen use, ApoE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000;54:1949-1954.
16. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156: 2213-2217.
17. Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999;52:965-970.
18. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 269:2637-2626.
19. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999;47:518-523.
20. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-267.
21. Mayeux R. Can estrogen or selective estrogen-receptor modulators preserve cognitive function in elderly women? N Eng J Med 2001;344:1242-1244.
22. Barrett-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc 1999;47:1289-1293.
23. Yaffe K, Grady D, Pressman A, Cummings S. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 1998;46:816-882.
24. Yaffe K, Lui LY, Grady D, et al. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet 2000;356:708-712.
25. Manly JJ, Merchant CA, Jacobs DM, et al. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000;54:833-837.
26. Senanarong V, Vannasaeng S, Poungvarin N, et al. Enodgenous estradiol in elderly individuals: cognitive and noncognitive associations. Arch Neurol 2002;59:385-389.
27. Geerlings MI, Ruitenberg A, Witteman JC, et al. Reproductive period and risk of dementia in postmenopausal women. JAMA 2001;285:1475-1481.
28. Treolar AE. Menstrual cyclicity and the pre-menopause. Maturitas 1981;3:249-264.
29. Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. Am J Epidemiol 1994;15:1091-1095.
30. Mann DM. The pathological association between Down's syndrome and Alzheimer disease. Mech Ageing Dev 1988;43:99-136.
31. Goldgaber D, Lerman MI, McBride WO, et al. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease, Down's syndrome and aging. J Neural Transm Suppl 1987;24:23-28.
32. Rumble B, Retallack R, Hillbach C, et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Eng J Med 1989;320:1446-1452.
33. Schupf N, Zigman W, Kapell D, et al. Early menopause in women with Down's syndrome. J Intellect Disabil Res 1997;41:264-267.
34. Lai F, Kammann E, Rebeck GW, et al. ApoE genotype and gender effects on Alzheimer disease in 100 adults with Down's syndrome. Neurology 1999;53:331-336.
35. Cosgrave MP, Tyrrell J, McCarron M, et al. Age at onset of dementia and age of menopause in women with Down's syndrome. J Intellect Disabil Res 1999;43:461-465.
36. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
37. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 1993;34:752-754.
38. Schupf N, Kapell D, Lee JH, et al. Onset of dementia is associated with apolipoprotein E epsilon 4 in Down's syndrome. Ann Neurol 1996;40:799-801.
39. Haxby JV. Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in nondemented old adults. J Menr Defic Res 1989;33:193-210.
40. Wisniewski KE, Hill AL. Clinical aspects of dementia in mental retardation and developmental disabilities. In Wisniewski H, Janicki M, editors. Aging and mental retardation. Baltimore, MD: Brookes, 1985:195-210.
41. Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 1972;12:543-550.
42. Dunn LM, Dunn LM. Peabody Picture Vocabulary Test-Revised. Circle Pines, MN: American Guidance Service, 1981.
43. McCarthy D. Scales of Children's Abilities. San Antonio, TX: Psychological Corporation, 1972.
44. Beery KE, Bukenia NA. Developmental Test of Visual-Motor Integration. Cleveland, OH: Modern Curriculum Press, 1989.
45. Wechsler D. Wechsler Intelligence Scale for Children-Revised. New York: Psychological Corporation, 1974.
46. Albert M, Cohen C. The Test for Severe Impairment: an instrument for the assessment of patients with severe cognitive dysfunction. J Am Geriatr Soc 1992;40:449-453.
47. Nihira K, Foster R, Shellhaas M, Leland H. AAMD Adaptive Behavior Scale. Washington, DC: American Association on Mental Deficiency, 1974.
48. Evenhuis HM, Kengen MMF, Eurlings HAL. Dementia Questionnaire for Mentally Retarded Persons. Zwanerdam, The Netherlands: Hooge Burch Institute for Mentally Retarded People, 1990.
49. Reiss S. Handbook of challenging behavior: mental health aspects of mental retardation. Worthington, OH: IDS Publishing, 1994.
50. Burt DB, Aylward EH. Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. J Intellect Disabil Res 2000;44:175-180.
51. WHO. World Health Organization International Classification of Diseases. Geneva: World Health Organization, 1980.
52. Stanford JL, Hartge P, Brinton LA, et al. Factors influencing the age at natural menopause. J Chronic Dis 1987;40:995-1002.
53. Cauley JA, Gutai JP, Kuller LH, et al. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-1131.
54. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984.
55. SPSS. SPSS 11.0 for Windows. Chicago, IL: SPSS, 2001.